Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuropsychiatric evolution after switch from dolutegravir to once-daily raltegravir (NEAR QD)
2017-003541-17Phase 4Active
- Sponsor
- Fundación IMABIS
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of raltegravir in human immunodeficiency virus infection (HIV), sponsored by Fundación IMABIS. Primary endpoints: Neuropsychiatric symptoms, Improvement in CNS symptoms at week 12 (DAIDS scale) and 1 more. Started Aug 2018; status: active.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2017-003541-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003541-17.